New drug tested for rare kidney disease halted early
Disease control
Terminated
This early-stage study tested a new drug called VB119 for adults with primary membranous nephropathy, a kidney disease that causes harmful protein loss in urine. The main goal was to find a safe dose and see how the body processes the drug. The study was terminated early and only…
Phase: PHASE1, PHASE2 • Sponsor: Tenet Medicines • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC